Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

A. Chiricozzi; M. Talamonti; Simone C. De; M. Galluzzo; N. Gori; G. Fabbrocini; A. V. Marzano; G. Girolomoni; A. Offidani; M. T. Rossi; L. Bianchi; A. Cristaudo; M. T. Fierro; L. Stingeni; G. Pellacani; G. Argenziano; A. Patrizi; P. Pigatto; M. Romanelli; Paola SAVOIA; P. Rubegni; C. Foti; N. Milanesi; Fortina A. Belloni; M. R. Bongiorno; T. Grieco; Nuzzo S. Di; M. C. Fargnoli; A. Carugno; A. Motolese; F. Rongioletti; P. Amerio; R. Balestri; C. Potenza; G. Micali; C. Patruno; I. Zalaudek; M. Lombardo; C. Feliciani; Nardo L. Di; F. Guarneri; K. Peris; G. Caldarola; D. Silvaggio; A. Dattola; M. Napolitano; S. M. Ferrucci; Bello G. Dal; T. Bianchelli; C. Rovati; F. Pigliacelli; M. Ortoncelli; K. Hansel; G. Calabrese; C. Loi; M. Iannone; F. Veronese; P. Romita; G. Tronconi; F. Caroppo; G. Tilotta; A. Sernicola; M. Esposito; F. Raponi; G. Gualdi; G. Rech; M. L. Musumeci; S. P. Nistico; A. Campitiello; L. Bonzano; V. Piras

doi:10.1111/all.14767

Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

A. Chiricozzi, M. Talamonti, Simone C. De, M. Galluzzo, N. Gori, G. Fabbrocini, A. V. Marzano, G. Girolomoni, A. Offidani, M. T. Rossi, L. Bianchi, A. Cristaudo, M. T. Fierro, L. Stingeni, G. Pellacani, G. Argenziano, A. Patrizi, P. Pigatto, M. Romanelli, Paola SAVOIAP. Rubegni, C. Foti, N. Milanesi, Fortina A. Belloni, M. R. Bongiorno, T. Grieco, Nuzzo S. Di, M. C. Fargnoli, A. Carugno, A. Motolese, F. Rongioletti, P. Amerio, R. Balestri, C. Potenza, G. Micali, C. Patruno, I. Zalaudek, M. Lombardo, C. Feliciani, Nardo L. Di, F. Guarneri, K. Peris, G. Caldarola, D. Silvaggio, A. Dattola, M. Napolitano, S. M. Ferrucci, Bello G. Dal, T. Bianchelli, C. Rovati, F. Pigliacelli, M. Ortoncelli, K. Hansel, G. Calabrese, C. Loi, M. Iannone, F. Veronese, P. Romita, G. Tronconi, F. Caroppo, G. Tilotta, A. Sernicola, M. Esposito, F. Raponi, G. Gualdi, G. Rech, M. L. Musumeci, S. P. Nistico, A. Campitiello, L. Bonzano, V. Piras

Department of Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.

Original language	English
Pages (from-to)	1813-1824
Number of pages	12
Journal	ALLERGY
Volume	76
Issue number	6
DOIs	https://doi.org/10.1111/all.14767
Publication status	Published - 2021

Keywords

Adult
COVID
COVID-19
Communicable Disease Control
Dermatitis, Atopic
Humans
Italy
Pandemics
Registries
SARS-CoV
SARS-CoV-2
atopic dermatitis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/all.14767

http://hdl.handle.net/11579/131259

Cite this

Chiricozzi, A., Talamonti, M., De, S. C., Galluzzo, M., Gori, N., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., ... Piras, V. (2021). Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry. ALLERGY, 76(6), 1813-1824. https://doi.org/10.1111/all.14767

@article{ae8af385b1d4486cb3a473a9f0584eb1,

title = "Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry",

abstract = "Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.",

keywords = "Adult, COVID, COVID-19, Communicable Disease Control, Dermatitis, Atopic, Humans, Italy, Pandemics, Registries, SARS-CoV, SARS-CoV-2, atopic dermatitis, Adult, COVID, COVID-19, Communicable Disease Control, Dermatitis, Atopic, Humans, Italy, Pandemics, Registries, SARS-CoV, SARS-CoV-2, atopic dermatitis",

author = "A. Chiricozzi and M. Talamonti and De, {Simone C.} and M. Galluzzo and N. Gori and G. Fabbrocini and Marzano, {A. V.} and G. Girolomoni and A. Offidani and Rossi, {M. T.} and L. Bianchi and A. Cristaudo and Fierro, {M. T.} and L. Stingeni and G. Pellacani and G. Argenziano and A. Patrizi and P. Pigatto and M. Romanelli and Paola SAVOIA and P. Rubegni and C. Foti and N. Milanesi and Belloni, {Fortina A.} and Bongiorno, {M. R.} and T. Grieco and Di, {Nuzzo S.} and Fargnoli, {M. C.} and A. Carugno and A. Motolese and F. Rongioletti and P. Amerio and R. Balestri and C. Potenza and G. Micali and C. Patruno and I. Zalaudek and M. Lombardo and C. Feliciani and Di, {Nardo L.} and F. Guarneri and K. Peris and G. Caldarola and D. Silvaggio and A. Dattola and M. Napolitano and Ferrucci, {S. M.} and Dal, {Bello G.} and T. Bianchelli and C. Rovati and F. Pigliacelli and M. Ortoncelli and K. Hansel and G. Calabrese and C. Loi and M. Iannone and F. Veronese and P. Romita and G. Tronconi and F. Caroppo and G. Tilotta and A. Sernicola and M. Esposito and F. Raponi and G. Gualdi and G. Rech and Musumeci, {M. L.} and Nistico, {S. P.} and A. Campitiello and L. Bonzano and V. Piras",

note = "Publisher Copyright: {\textcopyright} 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.",

year = "2021",

doi = "10.1111/all.14767",

language = "English",

volume = "76",

pages = "1813--1824",

journal = "ALLERGY",

issn = "0105-4538",

number = "6",

}

Chiricozzi, A, Talamonti, M, De, SC, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, AV, Girolomoni, G, Offidani, A, Rossi, MT, Bianchi, L, Cristaudo, A, Fierro, MT, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, SAVOIA, P, Rubegni, P, Foti, C, Milanesi, N, Belloni, FA, Bongiorno, MR, Grieco, T, Di, NS, Fargnoli, MC, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di, NL, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, SM, Dal, BG, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, ML, Nistico, SP, Campitiello, A, Bonzano, L & Piras, V 2021, 'Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry', ALLERGY, vol. 76, no. 6, pp. 1813-1824. https://doi.org/10.1111/all.14767

TY - JOUR

T1 - Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

AU - Chiricozzi, A.

AU - Talamonti, M.

AU - De, Simone C.

AU - Galluzzo, M.

AU - Gori, N.

AU - Fabbrocini, G.

AU - Marzano, A. V.

AU - Girolomoni, G.

AU - Offidani, A.

AU - Rossi, M. T.

AU - Bianchi, L.

AU - Cristaudo, A.

AU - Fierro, M. T.

AU - Stingeni, L.

AU - Pellacani, G.

AU - Argenziano, G.

AU - Patrizi, A.

AU - Pigatto, P.

AU - Romanelli, M.

AU - SAVOIA, Paola

AU - Rubegni, P.

AU - Foti, C.

AU - Milanesi, N.

AU - Belloni, Fortina A.

AU - Bongiorno, M. R.

AU - Grieco, T.

AU - Di, Nuzzo S.

AU - Fargnoli, M. C.

AU - Carugno, A.

AU - Motolese, A.

AU - Rongioletti, F.

AU - Amerio, P.

AU - Balestri, R.

AU - Potenza, C.

AU - Micali, G.

AU - Patruno, C.

AU - Zalaudek, I.

AU - Lombardo, M.

AU - Feliciani, C.

AU - Di, Nardo L.

AU - Guarneri, F.

AU - Peris, K.

AU - Caldarola, G.

AU - Silvaggio, D.

AU - Dattola, A.

AU - Napolitano, M.

AU - Ferrucci, S. M.

AU - Dal, Bello G.

AU - Bianchelli, T.

AU - Rovati, C.

AU - Pigliacelli, F.

AU - Ortoncelli, M.

AU - Hansel, K.

AU - Calabrese, G.

AU - Loi, C.

AU - Iannone, M.

AU - Veronese, F.

AU - Romita, P.

AU - Tronconi, G.

AU - Caroppo, F.

AU - Tilotta, G.

AU - Sernicola, A.

AU - Esposito, M.

AU - Raponi, F.

AU - Gualdi, G.

AU - Rech, G.

AU - Musumeci, M. L.

AU - Nistico, S. P.

AU - Campitiello, A.

AU - Bonzano, L.

AU - Piras, V.

PY - 2021

Y1 - 2021

N2 - Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.

AB - Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.

KW - Adult

KW - COVID

KW - COVID-19

KW - Communicable Disease Control

KW - Dermatitis, Atopic

KW - Humans

KW - Italy

KW - Pandemics

KW - Registries

KW - SARS-CoV

KW - SARS-CoV-2

KW - atopic dermatitis

KW - Adult

KW - COVID

KW - COVID-19

KW - Communicable Disease Control

KW - Dermatitis, Atopic

KW - Humans

KW - Italy

KW - Pandemics

KW - Registries

KW - SARS-CoV

KW - SARS-CoV-2

KW - atopic dermatitis

UR - https://iris.uniupo.it/handle/11579/131259

U2 - 10.1111/all.14767

DO - 10.1111/all.14767

M3 - Article

SN - 0105-4538

VL - 76

SP - 1813

EP - 1824

JO - ALLERGY

JF - ALLERGY

IS - 6

ER -

Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this